Pfizer Wins Obesity War Against NVO, to Buy Metsera for Around $10B
The heated bidding war between Pfizer PFE and Danish rival, Novo Nordisk NVO, related to the proposed acquisition of obesity drug developer Metsera MTSR is finally over. Metsera, a New York-based biotech, issued a press release stating that Pfizer has offered to acquire it for $86.25 per share (including cash and contingent value rights [CVR]) or more than $10 […]
STAT+: Medicaid’s ‘GENEROUS’ pricing may not save states money
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Morning, morning. Today, we have a trio of interesting studies on cholesterol reduction from the American Heart Association’s meeting in New Orleans. Also, Pfizer wins the Metsera deal with $10 billion, and we look […]
GLP-1 drugs effective for weight loss, but more independent studies needed
Three new Cochrane reviews find evidence that GLP-1 drugs result in clinically meaningful weight loss, but industry-funded studies raise questions. The reviews were commissioned by the World Health Organization (WHO) to inform upcoming guidelines on the use of these drugs to treat obesity. The reviews, which examine the effects of three weight loss drugs known […]
Does Trump’s MFN Policy Put Pharma ETFs in the Crosshairs?
Pharma giants Eli Lily (LLY) and Novo Nordisk (NVO) have signed deals with U.S. President Donald Trump to slash the prices of some of their obesity drugs, including upcoming pills, as per a White House announcement made late last week. This comes as part of the Trump administration’s Most-Favored-Nation (“MFN”) drug pricing policy that aims […]
STAT+: Pharmalittle: We’re reading about a Merck cholesterol pill, the Trump deal for obesity drugs, and more
Good morning, everyone, and welcome to another working week. We hope the weekend respite was relaxing and invigorating, because that oh-so familiar routine of deadlines, online meetings, and phone calls has predictably returned. But what can you do? The world, such as it is, continues to spin. So time to give it a nudge in […]
GPs Urge Specialist Clinics for Weight-Loss Drug Use
At the RCGP Annual Conference, GPs backed specialist-led clinics for prescribing GLP-1 weight-loss drugs, warning against online misuse and over-medicalising obesity. Medscape News UK
Is the White House’s deal with pharma on GLP-1 drugs a game changer? – statnews.com
Is the White House’s deal with pharma on GLP-1 drugs a game changer? statnews.com
The next-generation weight loss drug that’s ‘as effective as Mounjaro – WITHOUT Ozempic side effect’
A NEW weight loss drug may offer a tempting alternative to popular GLP-1 drugs like Ozempic and Wegovy. The once-weekly injection has been shown to be as effective as Mounjaro – but patients don’t experience one of the least-favourable side effects of weight loss jabs. Eloralintide, an amylin analog injection that’s been produced by Eli…
Camurus jumps on positive topline result for its once-monthly GLP-1 candidate – TradingView
Camurus jumps on positive topline result for its once-monthly GLP-1 candidate TradingView
STAT+: Is the White House’s deal with pharma on GLP-1 drugs a game changer?
President Trump last week hailed his deal with pharma companies to cut the price of blockbuster weight loss drugs as a major win for his administration and for increasing drug affordability. The question is how big of a difference the agreement will make for patients. The deal is expected to significantly expand access to GLP-1 […]